BUENA, N.J.--(BUSINESS WIRE)--IGI Laboratories, Inc. (NYSE AMEX:IG), a premier provider of topical formulation development, analytical, manufacturing and packaging services today announced that effective February 12, 2010, Charles E. Moore has joined the Company in the newly created position of Executive Vice President of Technical Operations. Mr. Moore will report directly to Chief Executive Officer, Hem Pandya. In addition, the Company announced the promotion of Philip S. Forte to Chief Financial Officer. These key executive appointments will facilitate the next phase of the Company’s growth into becoming a leader in the topical and oral liquid pharmaceutical market.
Commenting on today's news, Mr. Pandya noted, "We are very pleased to welcome Charlie to IGI’s executive team. With over 25 years of pharmaceutical industry experience specifically in the field of dermatology, Charlie is a seasoned executive with a broad knowledge base in the areas of product development, commercial operations, logistics, business development, and sales. I would also like to congratulate Phil and look forward to working with him in his role as Chief Financial Officer. Phil as been a tremendous asset to the Company ever since joining IGI as Corporate Controller in May 2009. Together as a team we will successfully execute on the Company's business strategies."
Charles E. Moore is an experienced pharmaceutical executive with a successful track record in bringing over 50 generic topical products from development to approval. Prior to joining IGI, Mr. Moore was Vice President of Business Development for Infa Inc. where he was responsible for development of the North American business of the Infa Group, an Italian-based Active Pharmaceutical Ingredient (API) manufacturer. Mr. Moore has also served as Director of Business Development for VinChem Inc. From 1980 to 2006, Mr. Moore served in various senior management roles for Altana Inc. (now Nycomed) including being the Head of the Product Development Task Force. He was responsible for researching the US dermatology market, selecting the product candidates for in-house development, and overseeing the development process through ANDA approval and launch. Mr. Moore received his BSBA from Thomas A. Edison College.
Philip S. Forte is a financial professional with a 20 year record of? creating value in both the financial and operational side of various Pharmaceutical businesses. Prior to IGI, Mr. Forte was the Senior Director of Finance at Teva Specialty Pharmaceuticals Industries, Ltd., in Horsham Pennsylvania. At Teva Specialty Pharmaceuticals, Mr. Forte was responsible for the business financial operations including its strategic business plan and business development initiatives. Prior to Teva Specialty Pharmaceuticals, Mr. Forte has held various financial roles in corporate and public accounting including Bristol Myers Squibb and Aventis. Phil received his BBA in Accounting from Bernard M. Baruch and his MBA in finance from Fairleigh Dickinson University.